Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene

@article{Tatsuta2009CompleteEO,
  title={Complete elimination of established neuroblastoma by synergistic action of $\gamma$-irradiation and DCs treated with rSeV expressing interferon-$\beta$ gene},
  author={Kyosuke Tatsuta and S. Tanaka and Tatsuro Tajiri and Satoko Shibata and Atsushi Komaru and Yasuji Ueda and Makoto Inoue and Mamoru Hasegawa and Sachiyo Suita and Katsuo Sueishi and Tomoaki Taguchi and Yoshikazu Yonemitsu},
  journal={Gene Therapy},
  year={2009},
  volume={16},
  pages={240-251}
}
Dendritic cell (DC)-based immunotherapy has been investigated as a new therapeutic approach to intractable neuroblastomas; however, only limited clinical effect has been reported. To overcome the relatively low sensitivity of neuroblastomas against immunotherapy, we undertook a preclinical efficacy study to examine murine models to assess the combined effects of γ-irradiation pretreatment and recombinant Sendai virus (ts-rSeV/dF)-mediated murine interferon-β (mIFN-β) gene transfer to DCs using… 
Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.
TLDR
The combination of radiation and rSeV/DC therapy induces different effector cells, depending on the time point during treatment, which causes the tumor to increase in size from an early stage of treatment in the CD4+ and NK cell-depleted group to increased in size during treatment with γ-irradiation.
Antagonism of VEGF by Genetically Engineered Dendritic Cells Is Essential to Induce Antitumor Immunity against Malignant Ascites
TLDR
It is determined that the imbalance between the VEGF-A/vascular permeability factor and its decoy receptor, soluble fms-like tryrosine kinase receptor-1 (sFLT-1), was a major cause of MA resistance to dendritic cell (DC)-based immunotherapy.
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
TLDR
Different strategies of combining DC-therapy with immunomodulatory treatments will be discussed, hoping to improve and guide DC-based combination immunotherapies with the aim of further improving patient prognosis and care.
Title : Antagonism of VEGF by genetically engineered dendritic cells is essential to induce antitumor immunity against malignant ascitis
Malignant ascitis (MA) is a highly intractable and immunotherapy-resistant state of advanced gastrointestinal and ovarian cancers. Using a murine model of MA with CT26 colon cancer cells, we here
Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
Dendritic cells (DCs) are immune specialized cells playing a critical role in promoting immune response against antigens, and may represent important targets for therapeutic interventions in cancer.
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications
TLDR
Changes of the phenotype and microenvironment of tumor cells after exposure to irradiation, chemotherapeutic agents, and immune modulating agents rendering the tumor more immunogenic are summarized.
Dendritic cell therapy in cancer treatment; the state-of-the-art.
TLDR
The immunobiology of DC, and development of DC vaccines are first go through, and combinational approaches to enhance the efficacy of cancer treatment strategies are highlighted.
Efficacy of dendritic cell-based immunotherapy produced from cord blood in vitro and in a humanized NSG mouse cancer model.
TLDR
CD34-DCs from cord blood were sufficient in quantity and quality as a vaccine agent against tumors in vitro and in vivo and presented a better antitumor effect in vitro.
Recent developments in patented DC-based immunotherapy for various malignancies
TLDR
This review focuses primarily on patents analysis of recently developed DC-based cancer immunotherapies and analyzes the critical factors of DC- based cancer immunotherapy to best optimize the development of these novel technologies.
Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells
TLDR
A possible breakthrough is established, a simple cytokine-based culture method to expand the log-scale order of functional human DCs, and this concept of DC expansion should contribute significantly to the progress of DC immunotherapy.
...
1
2
3
...

References

SHOWING 1-10 OF 34 REFERENCES
Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-β Gene1
TLDR
Results indicate that rSeV is a new and powerful tool as an immune booster for DC-based cancer immunotherapy that can be significantly modified by IFN-β, and SeV/DC, therefore, warrants further investigation as a promising alternative for cancer Immunotherapy.
Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells.
TLDR
This is the first demonstration that non-transmissible SeV vector, SeV/dF, could be a DC-activator; DC/SeV/ dF-based cancer immunotherapy may, therefore, warrant further investigation.
Immunogenicity of Human Neuroblastoma
TLDR
It is shown that NB cells express tumor‐associated antigens, but lack constitutive expression of costimulatory molecules and surface HLA class I and II molecules, which indicates that the immunogenicity of human NB cells is very low but suggests that manipulation by cytokine administration or gene transfer can increase their immunogenic potential.
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
TLDR
It is demonstrated that it is feasible to generate large numbers of functional DC from pediatric patients even in those highly pretreated and with a large tumor burden, and the ability of the tumor lysate-pulsed DC to generate specific T-cell responses and to elicit regression of metastatic disease is demonstrated.
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
TLDR
Vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma and antigen-specific immunity was induced during DC vaccination.
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.
TLDR
The results demonstrate that the abscopal effect is in part immune mediated and that T cells are required to mediate distant tumor inhibition induced by radiation.
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
In this pilot study, we investigated the ability of autologous dendritic cells pulsed ex vivo with tumor–specific idiotype protein to stimulate host antitumor immunity when infused as a vaccine. Four
Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
TLDR
Induction chemotherapy followed by SCT according to the Japan Study Group for Advanced Neuroblastoma protocol improved the outcome of neuroblastomas with MYCN amplification; however, obtaining a further improvement in the long-term survival of stage 4 neuroblastoma may therefore require the development of an even more effective treatment modality.
Induction of acute phase gene expression by brain irradiation.
TLDR
The initial response of the brain to irradiation involves expression of inflammatory gene products, which are probably responsible for clinically observed early symptoms of brain radiotherapy.
Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification.
TLDR
High-dose combined chemotherapy based in part on the N-myc amplification status significantly improved the prognosis of patients with advanced neuroblastoma, however, stage IV patients with N- myc amplification still require a more effective treatment modality.
...
1
2
3
4
...